Authors
Sukhdeep S Basra, Tracy Y Wang, DaJuanicia N Simon, Karen Chiswell, Salim S Virani, Mahboob Alam, Vijay Nambi, Ali E Denktas, Anita Deswal, Biykem Bozkurt, Christie M Ballantyne, Eric D Peterson, Hani Jneid
Publication date
2018/6/19
Journal
Journal of the American Heart Association
Volume
7
Issue
12
Pages
e008125
Description
Background
Ticagrelor is a P2Y12 receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin.
Methods and Results
Patients in the acute coronary treatment and intervention outcomes network (ACTION) Registry‐Get With The Guidelines (GWTG) with acute myocardial infarction from October 2013 through December 2014 were included in the study (167 455 patients; 622 sites). We evaluated temporal trends in the prescription of P2Y12 inhibitors, and identified factors associated with ticagrelor use at discharge. Among patients discharged on ticagrelor and aspirin (21 262 patients), we evaluated the temporal trends and independent factors associated with high‐dose aspirin prescription at discharge. Ticagrelor prescription at discharge increased significantly from 12% to 16.7% (P<0.0001). Decreases in …
Scholar articles
SS Basra, TY Wang, DJN Simon, K Chiswell, SS Virani… - Journal of the American Heart Association, 2018